The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302) Meeting Abstract


Authors: Nishihori, T.; Bashir, Q.; Pasquini, M. C.; Martens, M.; Wu, J.; Alsina, M.; Efebera, Y. A.; Gasparetto, C.; Geller, N.; Giralt, S.; Koreth, J.; McCarthy, P. L.; Scott, E. C.; Stadtmauer, E. A.; Vesole, D. H.; Hari, P.
Abstract Title: The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302)
Meeting Title: 2021 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 39
Issue: 15 Suppl.
Meeting Dates: 2021 Jun 4-8
Meeting Location: Virtual
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2021-05-20
Language: English
ACCESSION: WOS:000708120604052
DOI: 10.1200/JCO.2021.39.15_suppl.7003
PROVIDER: wos
Notes: Meeting Abstract: 7003 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sergio Andres Giralt
    1063 Giralt